The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

The determinants of recent gains in cancer survival: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

Print

Sub-category:
Health Services Research

Category:
Health Services Research

Meeting:
2008 ASCO Annual Meeting

Session Type and Session Title:
General Poster Session, Health Services Research

Abstract No:
6616

Citation:
J Clin Oncol 26: 2008 (May 20 suppl; abstr 6616)

Author(s):
E. Sun, D. Lakdawalla, C. Reyes, D. Goldman, T. Philipson, A. Jena

Abstract:

Background: Although cancer remains a leading cause of death, the last few decades have seen improvements in the diagnosis and treatment of the disease. We measure the gains in cancer survival over the last 20 years, and separate these gains into the portions due to improvements in treatment and detection. Methods: We used data from the Surveillance, Epidemiology, and End Results database to calculate cancer survival over time. Our analysis focused on improvements in survival for non-Hodgkin's Lymphoma (NHL), breast cancer, colon cancer, pancreatic cancer, lung cancer, and all cancers combined. Due to data limitations, we calculated survival gains between 1990 and 2000 for NHL, lung cancer, and all cancers combined, and gains between 1980 and 2000 for the remaining cancers. To separate these gains into the portions due to improvements in treatment and detection, we applied the tumor stage data in SEER, which allows us to calculate survival conditional on stage of diagnosis. Since improvements in detection shift the distribution of patients into earlier stages, any improvements in survival conditional on diagnosis at a particular stage are likely to be due to advances in treatment, rather than detection. This empirical approach allows us to separate survival gains into the portions due to improved treatment and detection. Results: We observed large gains in survival during this time period, and most of the gains appear to have been driven by improvements in treatment. The table below summarizes our results. *1990 to 2000. Conclusions: In the past decades, gains in cancer survival have been largely driven by improvements in treatment, even for some cancers (breast and colon) for which there have been increased efforts to improve detection. In these latter cases, the results are attributable to both progress in detection and the surprisingly rapid improvement in survival at every given stage of diagnosis.

CancerGain in Life Expectancy
1980-2000 (Years)
Gain Due to Improved
Treatment (%)
All*2.9-3.079-86%
Breast5.9-6.090-93%
Colon2.8-3.265-75%
Lung *0.4-0.581-91%
NHL*3.1-3.691-98%
NHL (Aggressive) *2.8-3.395-100%
NHL (Indolent) *3.6-4.895-100%
Pancreatic0.6    71%


Abstract Disclosures

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the print version.


  Associated Presentation(s):

    

1. The determinants of recent gains in cancer survival: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

Meeting: 2008 ASCO Annual Meeting
Presenter: Eric Sun, PhD
Session: Health Services Research (General Poster Session)


  Other Abstracts in this Sub-Category:

    

1. Preventive care for breast cancer survivors versus controls: Changes between 1998 and 2002.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 6501   First Author: C. F. Snyder
Category: Health Services Research

    

2. Economic analysis of the Clinical Outcomes of Surgical Therapy (COST) trial comparing laparoscopically-assisted colectomy (LAC) with open colectomy (OC) for colon cancer.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 6502   First Author: J. C. Weeks
Category: Health Services Research

    

3. Oncology health care and patient out-of-pocket cost trends in a commercially insured population.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 6503   First Author: V. J. Willey
Category: Health Services Research

    

More...


  Abstracts by E. Sun :

    

1. Associations between laboratory blood data and effectiveness of preoperative chemoradiotherapy in advanced rectal cancer.

Meeting: 2010 Gastrointestinal Cancers Symposium   Abstract No: 497   First Author: J. Kitayama
Category: Cancers of the Colon and Rectum - Multidisciplinary Treatment

    

2. A phase II clinical trial utilizing maximum medical and surgical cytoredutive treatments for patients with metastatic colorectal cancer to the liver.

Meeting: 2009 ASCO Annual Meeting   Abstract No: e15130   First Author: S. D. Glisson
Category: Gastrointestinal (Colorectal) Cancer - Colorectal Cancer (including liver metastases)

    

3. The determinants of recent gains in cancer survival: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 6616   First Author: E. Sun
Category: Health Services Research

    

More...


  Presentations by E. Sun :

    

1. The determinants of recent gains in cancer survival: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

Meeting: 2008 ASCO Annual Meeting
Presenter: Eric Sun, PhD
Session: Health Services Research (General Poster Session)

    

More...


  Educational Book Manuscripts by E. Sun :

    

No items found.




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.